These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30318690)

  • 1. Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator?
    Orfanoudaki E; Drygiannakis I; Koutroubakis IE
    Aliment Pharmacol Ther; 2018 Nov; 48(9):1037-1038. PubMed ID: 30318690
    [No Abstract]   [Full Text] [Related]  

  • 2. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
    Guerra Veloz MF; Argüelles-Arias F; Castro Laria L; Maldonado Pérez B; Benítez Roldan A; Perea Amarillo R; Merino Bohórquez V; Calleja MA; Caunedo Álvarez Á; Vilches Arenas Á
    World J Gastroenterol; 2018 Dec; 24(46):5288-5296. PubMed ID: 30581277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France.
    Avouac J; Moltó A; Abitbol V; Etcheto A; Salcion A; Gutermann L; Klotz C; Elhai M; Cohen P; Soret PA; Morin F; Conort O; Chast F; Goulvestre C; Jeunne CL; Chaussade S; Kahan A; Roux C; Allanore Y; Dougados M
    Semin Arthritis Rheum; 2018 Apr; 47(5):741-748. PubMed ID: 29102156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
    Gecse KB; Lovász BD; Farkas K; Banai J; Bene L; Gasztonyi B; Golovics PA; Kristóf T; Lakatos L; Csontos ÁA; Juhász M; Nagy F; Palatka K; Papp M; Patai Á; Lakner L; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Szalay B; Molnár T; Lakatos PL
    J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.
    Sieczkowska J; Jarzębicka D; Banaszkiewicz A; Plocek A; Gawronska A; Toporowska-Kowalska E; Oracz G; Meglicka M; Kierkus J
    J Crohns Colitis; 2016 Feb; 10(2):127-32. PubMed ID: 26721942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter: SPOSIB SB2-a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2.
    Macaluso FS; Cappello M; Giuffrida E; Fries W; Centritto A; Privitera AC; Inserra G; Vassallo R; Magnano A; Vinci E; Garufi S; Ventimiglia M; Renna S; Orlando R; Rizzuto G; Cottone M; Orlando A;
    Aliment Pharmacol Ther; 2019 Jan; 49(2):234-236. PubMed ID: 30589969
    [No Abstract]   [Full Text] [Related]  

  • 7. The nocebo effect challenges the non-medical infliximab switch in practice.
    Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA
    Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission.
    Guerrero Puente L; Iglesias Flores E; Benítez JM; Medina Medina R; Salgueiro Rodríguez I; Aguilar Melero P; Cárdenas Aranzana MJ; González Fernández R; Manzanares Martin B; García-Sánchez V
    Gastroenterol Hepatol; 2017 Nov; 40(9):595-604. PubMed ID: 28865888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with Biosimilar Infliximab (Remsima®) in Norway.
    Jahnsen J; Kaasen Jørgensen K
    Dig Dis; 2017; 35(1-2):83-90. PubMed ID: 28147374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ANVISA APPROVES THE FIRST BIOSIMILAR MONOCLONAL ANTIBODY BASED ON COMPARABILITY IN BRAZIL.
    Teixeira FV; Kotze PG; Damião AO
    Arq Gastroenterol; 2016; 53(2):60-1. PubMed ID: 27305409
    [No Abstract]   [Full Text] [Related]  

  • 13. Infliximab Biosimilars in the Age of Personalized Medicine.
    Kang J; Pisupati K; Benet A; Ruotolo BT; Schwendeman SP; Schwendeman A
    Trends Biotechnol; 2018 Oct; 36(10):987-992. PubMed ID: 29861288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
    Ratnakumaran R; To N; Gracie DJ; Selinger CP; O'Connor A; Clark T; Carey N; Leigh K; Bourner L; Ford AC; Hamlin PJ
    Scand J Gastroenterol; 2018 Jun; 53(6):700-707. PubMed ID: 29687730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.
    Danese S; Fiorino G; Raine T; Ferrante M; Kemp K; Kierkus J; Lakatos PL; Mantzaris G; van der Woude J; Panes J; Peyrin-Biroulet L
    J Crohns Colitis; 2017 Jan; 11(1):26-34. PubMed ID: 27927718
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.
    Farkas K; Molnár T
    Immunotherapy; 2018 Feb; 10(2):107-117. PubMed ID: 29124994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab biosimilar CT-P13 for inflammatory bowel disease.
    Bonovas S; Peyrin-Biroulet L; Danese S
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):373-375. PubMed ID: 29606565
    [No Abstract]   [Full Text] [Related]  

  • 20. Biosimilars: in support of extrapolation of indications.
    Ebbers HC
    J Crohns Colitis; 2014 May; 8(5):431-5. PubMed ID: 24594005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.